Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490665 | 0.82 | LDHA (0.59) | HTR2ACYP3A4TAAR1LDHA | |
| SCHEMBL6600354 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL490808 | 0.81 | HSD17B10 (0.55) | ALDH1A1TSHRHTR2ASMN1; SMN2TAAR1 | |
| SCHEMBL491054 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL10320769 | 0.81 | NPC1 (0.52) | ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL1186888 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL490522 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRHTR2ACYP3A4CA2 | |
| SCHEMBL2673221 | 0.79 | ALDH1A1 (0.49) | ALDH1A1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL7823025 | 0.78 | LDHA (0.58) | TSHRHTR2ACYP3A4TAAR1LDHA | |
| SCHEMBL491026 | 0.78 | LDHA (0.71) | ALDH1A1SMN1; SMN2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238964-A2 | Stabilised cosmetic compounds | Henkel AG & Co. KGaA (DE) | 2010-10-13 | — | — | EP | claimed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2238964-A2 | Stabilised cosmetic compounds | Henkel AG & Co. KGaA (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| US-4376777-A | Thiazolidine derivatives use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-03-15 | — | — | US | disclosed |
| EP-0032128-A1 | Thiazolidine derivatives and their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | ALDH1A1 181/4885TSHR 4679/4885HTR2A 4534/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | ALDH1A1 314/4885TSHR 4810/4885HTR2A 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.